Avadel Pharmaceuticals Announces Publication Of Data In 'Sleep Medicine' Highlighting Efficacy Of LUMRYZ Extended-Release Oral Suspension In Improving Narcolepsy Symptoms Regardless Of Concomitant Use Of An Alerting Agent
Portfolio Pulse from Benzinga Newsdesk
Avadel Pharmaceuticals published data in 'Sleep Medicine' showing the efficacy of LUMRYZ in improving narcolepsy symptoms, regardless of alerting agent use. The Phase 3 REST-ON trial confirmed significant improvements in wakefulness and reduced cataplexy episodes.
September 25, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avadel Pharmaceuticals' LUMRYZ demonstrated significant efficacy in treating narcolepsy symptoms in the Phase 3 REST-ON trial, regardless of alerting agent use. This could enhance the product's market potential and investor interest.
The publication of positive Phase 3 trial results for LUMRYZ, showing efficacy in treating narcolepsy symptoms, is likely to boost investor confidence and interest in Avadel Pharmaceuticals. This could lead to a positive short-term impact on AVDL's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100